LXEO vs NTLA
LXEO: Lexeo Therapeutics is a clinical-stage genetic medicine company developing pioneering gene therapies for cardiovascular diseases with high unmet needs. NTLA: Intellia Therapeutics is a genome editing pioneer developing CRISPR/Cas9-based, potentially curative in vivo therapies for genetic diseases.
Side-by-side fundamentals
| Metric | LXEO | NTLA | Edge |
|---|---|---|---|
| Price as of 2026-10-21 close | $3.00 | $11.65 | |
| Market cap | $246M | $1.6B | |
| Net margin | -9063.8% | -609.9% | NTLA higher |
| Operating margin | -9252.1% | -651.7% | NTLA higher |
| ROE FY2025, SEC XBRL | -40.5% | -61.5% | LXEO higher |
| ROA FY2025, SEC XBRL | -37.2% | -49.0% | LXEO higher |
| Revenue growth (YoY) FY2025, SEC XBRL | n/a | +16.9% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +9.1% | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 2.01 | 1.66 | |
| 1-year return as of 2026-10-21 close | -68.8% | -56.8% | NTLA higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.